» Articles » PMID: 35812457

Impact of Chronic Inflammation in Psoriasis on Bone Metabolism

Overview
Journal Front Immunol
Date 2022 Jul 11
PMID 35812457
Authors
Affiliations
Soon will be listed here.
Abstract

Psoriasis is a chronic inflammatory disease of the skin and joints associated with several comorbidities such as arthritis, diabetes mellitus and metabolic syndrome, including obesity, hypertension and dyslipidaemia, Crohn's disease, uveitis and psychiatric and psychological diseases. Psoriasis has been described as an independent risk factor for cardiovascular diseases and thus patients with psoriasis should be monitored for the development of cardiovascular disease or metabolic syndrome. However, there is mounting evidence that psoriasis also affects the development of osteoporosis, an important metabolic disease with enormous clinical and socioeconomic impact. At present, there are still controversial opinions about the role of psoriasis in osteoporosis. A more in depth analysis of this phenomenon is of great importance for affected patients since, until now, bone metabolism is not routinely examined in psoriatic patients, which might have important long-term consequences for patients and the health system. In the present review, we summarize current knowledge on the impact of psoriatic inflammation on bone metabolism and osteoporosis.

Citing Articles

Management of Systemic Anti-psoriatic Drugs in Psoriasis Patients with Concurrent Paraplegia or Tetraplegia: Insights From a 6-Year Multicenter, Retrospective Observational Study.

Damiani G, Pacifico A, Ricciardi S, Corazza V, Trigos D, Fiore M Dermatol Ther (Heidelb). 2025; 15(2):427-436.

PMID: 39849247 PMC: 11832867. DOI: 10.1007/s13555-025-01338-w.


Skin Disorders and Osteoporosis: Unraveling the Interplay Between Vitamin D, Microbiota, and Epigenetics Within the Skin-Bone Axis.

Papa V, Li Pomi F, Minciullo P, Borgia F, Gangemi S Int J Mol Sci. 2025; 26(1.

PMID: 39796035 PMC: 11720247. DOI: 10.3390/ijms26010179.


Evaluation of nasal mucociliary clearance in patients with psoriasis.

Yucel A, Yavuz C, Gulluev M, Yucel H, Ozsoz E, Gencer Culha S Eur Arch Otorhinolaryngol. 2024; 282(2):807-811.

PMID: 39475967 DOI: 10.1007/s00405-024-09055-4.


Botulinum Toxin Treatment of Psoriasis-A Comprehensive Review.

Ghaseminejad-Bandpey A, Etemadmoghadam S, Jabbari B Toxins (Basel). 2024; 16(10).

PMID: 39453225 PMC: 11510791. DOI: 10.3390/toxins16100449.


Association between systemic immune-inflammation index and psoriasis: a population-based study.

Zhao X, Li J, Li X Front Immunol. 2024; 15:1305701.

PMID: 38504983 PMC: 10948528. DOI: 10.3389/fimmu.2024.1305701.


References
1.
Nowowiejska J, Baran A, Grabowska P, Lewoc M, Kaminski T, Flisiak I . Assessment of Life Quality, Stress and Physical Activity Among Patients with Psoriasis. Dermatol Ther (Heidelb). 2021; 12(2):395-406. PMC: 8850505. DOI: 10.1007/s13555-021-00662-1. View

2.
Takahashi T, Yamasaki K . Psoriasis and Antimicrobial Peptides. Int J Mol Sci. 2020; 21(18). PMC: 7555190. DOI: 10.3390/ijms21186791. View

3.
Paskins Z, Whittle R, Abdul Sultan A, Muller S, Blagojevic-Bucknall M, Helliwell T . Risk of fragility fracture among patients with late-onset psoriasis: a UK population-based study. Osteoporos Int. 2018; 29(7):1659-1664. DOI: 10.1007/s00198-018-4491-z. View

4.
Kim H, Lee Y, Kim M, Kwon J, Song M, Lee Z . Extracellular S100A4 negatively regulates osteoblast function by activating the NF-κB pathway. BMB Rep. 2016; 50(2):97-102. PMC: 5342873. DOI: 10.5483/bmbrep.2017.50.2.170. View

5.
Bowcock A, Cookson W . The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet. 2004; 13 Spec No 1:R43-55. DOI: 10.1093/hmg/ddh094. View